Anti-Gal: An abundant human natural antibody of multiple pathogeneses and clinical benefits

Immunology

Volumn 140, Issue 1, 2013, Pages 1-11

  Galili, Uri ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

gal epitopes; Anti Gal; Increased immunogenicity; Tumour vaccine; Wound healing

Indexed keywords

ALPHA GAL GLYCOLIPID; ALPHA GAL NANOPARTICLE; ANTIBODY; APHA GAL EPITOPE; CETUXIMAB; EPITOPE; GAL ANTIBODY; GLYCOLIPID; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; NANOPARTICLE; PHOSPHOLIPID ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALLERGIC REACTION; ALLERGY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; APE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BURN; CANCER IMMUNOTHERAPY; CHAGAS DISEASE; COMPLEMENT ACTIVATION; DRUG DOSE ESCALATION; ERYTHROCYTE; GRAFT REJECTION; GRAVES DISEASE; HAPLORHINI; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOGENICITY; INFLAMMATION; KIDNEY CARCINOMA; MACROPHAGE ACTIVATION; NERVE INJURY; NONHUMAN; PANCREAS ADENOCARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROCYTE; THYROID CELL; TISSUE REGENERATION; TRYPANOSOMA CRUZI; WOUND; WOUND HEALING; XENOGRAFT;

Α-GAL EPITOPES; ANTI-GAL; INCREASED IMMUNOGENICITY; TUMOUR VACCINE; WOUND HEALING;

ANIMALS; ANTIBODIES, HETEROPHILE; AUTOIMMUNITY; CANCER VACCINES; CHAGAS DISEASE; EPITOPES; GRAVES DISEASE; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; IMMUNOGLOBULIN E; MAMMALS; REGENERATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS; TRISACCHARIDES; VIRAL VACCINES; WOUND HEALING;

EID: 84883221480     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12110     Document Type: Review

References (111)

1. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 1984; 160:1519-31.
2. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffis JM. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56:1730-7.
3. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993; 82:2485-93.
4. H3 and the presence of somatic mutations. J Immunol 1995; 155:1276-85.
5. Kearns-Jonker M, Swensson J, Ghiuzeli C et al. The human antibody response to porcine xenoantigens is encoded by IGHV3-11 and IGHV3-74 IgVH germline progenitors. J Immunol 1999; 163:4399-412.
6. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the anti-Gal antibody and the Galα1→3Gal epitope in primates. Proc Natl Acad Sci USA 1987; 84:1369-73.
7. Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1→3)-linked galactose residues. J Exp Med 1985; 162:573-82.
8. Spiro RG, Bhoyroo VD. Occurrence of α-d-galactosyl residues in the thyroglobulin from several species. Localization in the saccharide chains of the complex carbohydrate units. J Biol Chem 1984; 259:9858-66.
9. Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263:17755-62.
10. Basu M, Basu S. Enzymatic synthesis of blood group related pentaglycosyl ceramide by an α-galactosyltransferase. J Biol Chem 1973; 248:1700-6.
11. Blake DD, Goldstein IJ. An α-d-galactosyltransferase in Ehrlich ascites tumor cells. Biosynthesis and characterization of a trisaccharide (α-d-galacto(1-3)-N-acetyllactosamine). J Biol Chem 1981; 256:5387-93.
12. Betteridge A, Watkins WM. Two α-3-d galactosyltransferases in rabbit stomach mucosa with different acceptor substrate specificities. Eur J Biochem 1983; 132:29-35.
13. Galili U, Matta KL. Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. Transplantation 1996; 62:356-62.
14. Galili U. Evolution and pathophysiology of the human natural anti-Gal antibody. Springer Semin Immunopathol 1993; 15:155-71.
15. Galili U, Swanson K. Gene sequences suggest inactivation of α1-3 galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 1991; 88:7401-4.
16. Galili U, Andrews P. Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates. J Hum Evol 1995; 29:433-42.
17. Joziasse DH, Shaper JH, Jabs EW, Shaper NL. Characterization of an α1-3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene. J Biol Chem 1991; 266:6991-8.
18. Koike C, Fung JJ, Geller DA et al. Molecular basis of evolutionary loss of the α1, 3-galactosyltransferase gene in higher primates. J Biol Chem 2002; 277:10114-20.
19. Koike C, Uddin M, Wildman DE, Gray EA, Trucco M, Starzl TE, Goodman M. Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci USA 2007; 104:559-64.
20. Teranishi K, Manez R, Awwad M, Cooper DK. Anti-Gal α1-3Gal IgM and IgG antibody levels in sera of humans and old world non-human primates. Xenotransplantation 2002; 9:48-154.
21. Repik PM, Strizki JM, Galili U. Differential host dependent expression of α-galactosyl epitopes on viral glycoproteins: a study of Eastern equine encephalitis virus as a model. J Gen Virol 1994; 75:1177-81.
22. Galili U, Repik PM, Anaraki F, Mozdzanowska K, Washko G, Gerhard W. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine 1996; 14:321-8.
23. Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins MK. Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase. Nature 1996; 379:85-8.
24. Welsh RM, O'Donnell CL, Reed DJ, Rother RP. Evaluation of the Galα1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998; 72:4650-6.
25. Han W, Cai L, Wu B, Li L, Xiao Z, Cheng J, Wang PG. The wciN gene encodes an α-1, 3-galactosyltransferase involved in the biosynthesis of the capsule repeating unit of Streptococcus pneumoniae serotype 6B. Biochemistry 2012; 51:5804-10.
26. Posekany KJ, Pittman HK, Bradfield JF, Haisch CE, Verbanac KM. Induction of cytolytic anti-Gal antibodies in α-1, 3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria. Infect Immun 2002; 70:6215-22.
27. Almeida IC, Ferguson MA, Schenkman S, Travassos LR. Lytic anti- α-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem J 1994; 304:793-802.
28. Schneider P, Schnur LF, Jaffe CL, Ferguson MA, McConville MJ. Glycoinositol-phospholipid profiles of four serotypically distinct Old World Leishmania strains. Biochem J 1994; 304:603-9.
29. Avila JL, Rojas M, Galili U. Immunogenic Galα1-3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol. 1989; 142:2828-34.
30. Galili U, Korkesh A, Kahane I, Rachmilewitz A. Demonstration of a natural anti-galactosyl IgG antibody on thalassemic red blood cells. Blood 1983; 61:1258-64.
31. Galili U, Flechner I, Kniszinski A, Danon D, Rachmilewitz EA. The natural anti-α-galactosyl IgG on human normal senescent red blood cells. Br J Haematol 1986; 62:317-24.
32. Galili U, Clark MR, Shohet SB. Excessive binding of the natural anti-α-galactosyl IgG to sickle red cells may contribute to extravascular cell destruction. J Clin Invest 1986; 77:27-33.
33. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med 2008; 358:1109-17.
34. Commins SP, James HR, Kelly LA et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose. J Allergy Clin Immunol 2011; 127:1286-93.
35. Commins SP, Satinover SM, Hosen J, Mozena J, Borish L, Lewis BD, Woodfolk JA, Platts-Mills TA. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1, 3-galactose. J Allergy Clin Immunol 2009; 123:426-33.
36. Morisset M, Richard C, Astier C et al. Anaphylaxis to pork kidney is related to IgE antibodies specific for galactose-α-1, 3-galactose. Allergy 2012; 67:699-704.
37. Nuñez R, Carballada F, Gonzalez-Quintela A, Gomez-Rial J, Boquete M, Vidal C. Delayed mammalian meat-induced anaphylaxis due to galactose-α-1, 3-galactose in 5 European patients. J Allergy Clin Immunol 2011; 128:1122-4.
38. Tanemura M, Yin D, Chong AS, Galili U. Differential immune response to α-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest 2000; 105:301-10.
39. Wigglesworth K, Racki WJ, Mishra R, Szomolany-Tsuda E, Greiner DL, Galili U. Rapid recruitment and activation of macrophages by anti-Gal/α-gal liposome interaction accelerates wound healing. J Immunol 2011; 186:4422-32.
40. Galili U. Abnormal expression of α-galactosyl epitopes in man: a trigger for autoimmune processes? Lancet 1989; 2:358-61.
41. Etienne-Decerf J, Malaise M, Mahieu P, Winand R. Elevated anti-α-galactosyl antibody titres. A marker of progression in autoimmune thyroid disorders and in endocrine ophthalmopathy? Acta Endocrinol 1987; 115:67-74.
42. Winand RJ, Anaraki F, Etienne-Decerf J, Galili U. Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells. J Immunol 1993; 151:3923-34.
43. Thall A, Etienne-Decerf J, Winand RJ, Galili U. The α-galactosyl epitope on mammalian thyroid cells. Acta Endocrinol 1991; 124:692-9.
44. Winand RJ, Winand-Devigne J, Meurisse M, Galili U. Specific stimulation of Graves' disease thyrocytes by the natural anti-Gal antibody from normal and autologous serum. J Immunol 1994; 153:1386-95.
45. Sharma A, Naziruddin B, Cui MJ et al. Pig cells that lack the gene for α1-3 galactosyltransferase express low levels of the gal antigen. Transplantation 2003; 75:430-6.
46. Sandrin MS, Vaughan HA, Xing PX, McKenzie IF. Natural human anti-Gal α(1, 3)Gal antibodies react with human mucin peptides. Glycoconj J 1997; 14:97-105.
47. Lang J, Zhan J, Xu L, Yan Z. Identification of peptide mimetics of xenoreactive α-Gal antigenic epitope by phage display. Biochem Biophys Res Commun 2006; 344:214-20.
48. Davin JC, Malaise M, Foidart J, Mahieu P. Anti-α-galactosyl antibodies and immune complexes in children with Henoch-Schönlein purpura or IgA nephropathy. Kidney Int 1987; 31:1132-9.
49. D'Alessandro M, Mariani P, Lomanto D, Bachetoni A, Speranza V. Alterations in serum anti-α-galactosyl antibodies in patients with Crohn's disease and ulcerative colitis. Clin Immunol 2002; 103:63-8.
50. Towbin H, Rosenfelder G, Wieslander J et al. Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(α1-3)-galactose epitopes. J Exp Med 1987; 66:419-32.
51. Milani SR, Travassos LR. Anti-α-galactosyl antibodies in chagasic patients. Possible biological significance. Braz J Med Biol Res 1988; 21:1275-86.
52. Almeida IC, Milani SR, Gorin PA, Travassos LR. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-α-galactosyl antibodies. J Immunol 1991; 146:2394-400.
53. Gazzinelli RT, Pereira ME, Romanha A, Gazzinelli G, Brener Z. Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol 1991; 13:345-56.
54. Travassos LR, Almeida IC. Carbohydrate immunity in American trypanosomiasis. Springer Semin Immunopathol 1993; 15:183-204.
55. Souto-Padron T, Almeida IC, de Souza W, Travassos LR. Distribution of α-galactosyl epitopes on Trypanosoma cruzi trypomastigotes and amastigotes forms for infected Vero cells detected by chagasic antibodies. J Eukaryot Microbiol 1994; 41:47-54.
56. Avila JL. α-Galactosyl-bearing epitopes as potent immunogens in Chagas' disease and leishmaniasis. Subcell Biochem 1999; 32:173-213.
57. Ramasamy R, Field MC. Terminal galactosylation of glycoconjugates in Plasmodium falciparum asexual blood stages and Trypanosoma brucei bloodstream trypomastigotes. Exp Parasitol 2012; 130:314-20.
58. Lüderitz O, Simmons DA, Westphal G. The immunochemistry of Salmonella chemotype VI O-antigens. The structure of oligosaccharides from Salmonella group U (o 43) lipopolysaccharides. Biochem J 1965; 97:820-6.
59. Tanemura M, Maruyama S, Galili U. Differential expression of α-gal epitopes (Galα1-3Galß1-4GlcNAc-R) on pig and mouse organs. Transplantation 2000; 69:187-90.
60. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotranplantation in humans. Immunol Today 1993; 14:480-2.
61. Good AH, Cooper DK, Malcolm AJ et al. Identification of carbohydrate structures which bind human anti-porcine antibodies: implication for discordant xenografting in man. Transplant Proc 1992; 24:559-62.
62. Sandrin M, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Galα1-3Gal epitopes. Proc Natl Acad Sci USA 1993; 90:11391-5.
63. Collins BH, Cotterell AH, McCurry KR et al. Cardiac xenografts between primate species provide evidence of the α-galactosyl determinant in hyperacute rejection. J Immunol 1994; 154:5500-10.
64. Xu Y, Lorf T, Sablinski T et al. Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Galα1-3Galβ1-4Glc-R immunoaffinity column. Transplantation 1998; 65:172-9.
65. Lai L, Kolber-Simonds D, Park KW et al. Production of α-1, 3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295:1089-92.
66. Phelps CJ, Koike C, Vaught TD et al. Production of α1, 3-galactosyltransferase-deficient pigs. Science 2003; 299:411-4.
67. Kuwaki K, Tseng L, Dor FJ et al. Heart transplantation in baboons using α1, 3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11:29-31.
68. Yamada K, Yazawa K, Shimizu A et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of α1, 3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11:32-4.
69. Chen G, Qian H, Starzl H et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11:1295-8.
70. Tseng YL, Kuwaki K, Dor FJ et al. α1, 3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005; 80:493-500.
71. Galili U. Induced anti-non gal antibodies in human xenograft recipients. Transplantation 2012; 93:11-6.
72. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3:282-6.
73. Cooper DK, Keogh AM, Brink J et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000; 19:1125-65.
74. Jamieson WR, Rosado LJ, Munro AI et al. Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups. Ann Thorac Surg 1988; 46:155-62.
75. Konakci KZ, Bohle B, Blumer R et al. α-Gal on bioprosthesis: xenograft immune response in cardiac surgery. Eur J Clin Invest 2005; 35:17-23.
76. Lila N, McGregor CG, Carpentier S et al. Gal knockout pig pericardium: new source of material for heart valve bioprostheses. J Heart Lung Transplant 2010; 29:538-43.
77. McGregor CG, Carpentier A, Lila N, Logan JS, Byrne GW. Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. J Thorac Cardiovasc Surg 2011; 141:269-75.
78. Galili G, LaTemple DC. The natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997; 18:281-5.
79. Abdel-Motal UM, Wigglesworth K, Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 2009; 27:3072-82.
80. Abdel-Motal UM, Guay HM, Wigglesworth K, Welsh RM, Galili U. Increased immunogenicity of influenza virus vaccine by anti-Gal mediated targeting to antigen presenting cells. J Virol 2007; 81:9131-41.
81. Abdel-Motal UM, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galα1-3Galβ1-4GlcNAc-R epitopes. J Virol 2006; 80:6943-51.
82. Abdel-Motal UM, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α-gal epitopes. Vaccine 2010; 28:1758-65.
83. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:719-24.
84. Nik-Zainal S, Van Loo P, Wedge DC et al. The life history of 21 breast cancers. Cell 2012; 149:994-1007.
85. Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 1996; 8:289-93.
86. thor Straten P, Becker JC, Guldberg P, Zeuthen J. In situ T cells in melanoma. Cancer Immunol Immunother 1999; 48:386-95.
87. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13.
88. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4.
89. Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8.
90. LaTemple DC, Abrams JT, Zhang SU, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knock out mice for α1, 3galactosyltranferase. Cancer Res 1999; 59:3417-23.
91. Deriy L, Ogawa H, Gao G, Galili U. In vivo targeting of vaccinating tumor cells to antigen presenting cells by a gene therapy method with adenovirus containing the α1, 3galactosyltransferase gene". Cancer Gene Ther 2005; 12:528-39.
92. Rossi GR, Mautino MR, Unfer RC et al. Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1, 3)-galactosyl epitopes. Cancer Res 2005; 65:10555-61.
93. Deguchi T, Tanemura M, Miyoshi E et al. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express α-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res 2010; 70:5259-69.
94. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of α-galactosyl epitopes by recombinant α1, 3galactosyltransferase for opsonization of human tumor cell vaccines by anti-Gal. Cancer Res 1996; 56:3069-74.
95. Manches O, Plumas J, Lui L et al. Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy with autologous tumor cells. Haematologica 2005; 90:625-34.
96. Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 2007; 178:4676-87.
97. Galili U, Albertini M, Sondel P, Wigglesworth K, Sullivan M, Whalen G. In situ conversion of melanoma lesions into autologous vaccine by intratumoral injections of α-gal glycolipids. Cancers 2010; 2:773-93.
98. Abdel-Motal UM, Wigglesworth K, Galili U. Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother 2009; 58:1545-56.
99. Rossi GR, Unfer RC, Seregina T, Link CJ. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1, 3)galactosyl epitopes. Cancer Immunol Immunother 2005; 54:999-1009.
100. Markiewski MM, DeAngelis RA, Benencia F et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9:1225-35.
101. Whalen GF, Sullivan M, Piperdi B, Wasseff W, Galili U. Cancer immunotherapy by intratumoral injection of α-gal glycolipids. Anticancer Res 2012; 32:3861-8.
102. Galili U, Wigglesworth K, Abdel-Motal UM. Accelerated healing of skin burns by anti-Gal/α-gal liposomes interaction. Burns 2010; 36:239-51.
103. Hurwitz Z, Ignotz R, Lalikos J, Galili U. Accelerated porcine wound healing with α-Gal nanoparticles. Plast Reconstr Surg 2012; 129:242-51.
104. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 41:738-40.
105. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005; 15:599-607.
106. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008; 453:314-21.
107. Elkon KB, Silverman GJ. Naturally occurring autoantibodies to apoptotic cells. Adv Exp Med Biol 2012; 750:14-26.
108. Minatoguchi S, Takemura G, Chen XH et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004; 109:2572-80.
109. Dewald O, Zymek P, Winkelmann K et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005; 96:881-9.
110. Yano T, Miura T, Whittaker P et al. Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol 2006; 47:626-34.
111. Dray C, Rougon G, Debarbieux F. Qunatitative analysis by in vivo imaging of the dynamics of vascular and axonal networks in injured mouse spinal cord. Proc Natl Acad Sci USA 2009; 106:9459-64.